Alnylam Pharmaceuticals (ALNY) recently announced its Q4 financial results, revealing a Non-GAAP EPS of $1.25, which fell short of analyst expectations by $0.25. Despite this, the company reported a substantial year-over-year revenue increase of 83.8%, reaching $1.09 billion, although this figure missed estimates by $70 million. Looking forward, Alnylam is optimistic about its growth trajectory, projecting total net product revenues for 2026 to range between $4.9 billion and $5.3 billion, with anticipated growth of 64% to 77% compared to 2025. Additionally, the company forecasts revenues from collaborations and royalties to be between $400 million and $500 million.
https://www.gurufocus.com/news/8610763/alnylam-pharmaceuticals-alny-q4-earnings-miss-estimates
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.